Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

LUNG

+ Watchlist+ Portfolio

Pulmonx Corp.

Regulated industryPhysical productsSells to businessesTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$2.74
52-Week Range
$1.13 – $3.25
Market Cap
$117.15M
P/E (TTM)
—
EPS (TTM)
-1.01
Dividend Yield
0.00%
Advanced Metrics
Price/Book
3.43
PEG Ratio
—
Return on Equity
-90.31%
Return on Assets
-19.82%
Gross Margin
77.42%
Operating Margin
-44.39%
Profit Margin
-47.93%
Current Ratio
4.05
Debt/Equity
1.65
Total Debt
$56.35M
Free Cash Flow
$-9.47M
Revenue Growth
6.20%
Earnings Growth
—
Enterprise Value
$120.81M

Market Snapshot

About

Pulmonx Corp. is a commercial-stage medical technology company focused on minimally invasive treatments for chronic obstructive pulmonary disease (COPD) and emphysema. The company developed the Zephyr Endobronchial Valve, a small one-way valve implanted in the airways to help severe emphysema patients breathe more easily. Their products are designed to reduce lung hyperinflation without surgery.